- Drug: Omvoh (mirikizumab-mrkz)
- Manufacturer: Lilly
- Route of Administration: Intravenous, Subcutaneous
- Site of Care: Outpatient
- Approved Indication:
- treatment of moderately to severely active Crohn’s disease in adults
- treatment of moderately to severely active ulcerative colitis in adults
- Disease: Crohn’s disease, ulcerative colitis
- Therapeutic Area: Gastroenterology, Rheumatology, Dermatology
- Enrollment Form Link: omvoh.lilly.com/resources
- Phone Number: 1-800-LillyRx (1-800-545-5979)
- Fax Number: 1-844-466-0006
- Product Website: omvoh.com